A phase I/II study of capecitabine (Cape), oxaliplatin (Ox), panitumumab (Pmab), and external beam radiation therapy (RT) for patients with esophagogastric carcinoma (EC).
Brian G. Czito
Research Funding - Amgen
Christopher Willett
No relevant relationships to disclose
Manisha Palta
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Shannon McCall
No relevant relationships to disclose
Nathan Gee
No relevant relationships to disclose
Herbert Hurwitz
Consultant or Advisory Role - Amgen
Research Funding - Amgen
R Edward Coleman
No relevant relationships to disclose
Yousuf Zafar
No relevant relationships to disclose
Paula Kennedy-Newton
No relevant relationships to disclose
Hope Uronis
Research Funding - Amgen